Noviembre 2021: El primer ensayo clínico de la terapia celular del receptor de antígeno quimérico T (CAR-T) de próxima generación de cosecha propia de Corea del Sur, que está diseñado para eludir las señales del punto de control inmunitario, se puso en marcha recientemente.
El Instituto Avanzado de Ciencia y Tecnología de Corea (KAIST) anunció el miércoles que actualmente se está realizando un ensayo clínico de Fase 1b de su terapia con células CAR-T en el Centro Médico Samsung en Seúl. El ensayo se lleva a cabo con 10 pacientes coreanos que tienen linfoma difuso de células B grandes en recaída y refractario. Los derechos de comercialización del oleoducto fueron transferidos de la universidad a la empresa Curocell, cofundada por el profesor Kim Chan-hyuk. Curocell está a cargo del programa de desarrollo clínico del revolucionario inmunoterapia.
In addition, a Phase 2 ensayo clínico involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for receptor de antígeno quimérico T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Te puede gustar leer: Terapia de células T con CAR en Corea
Los hallazgos del estudio se presentaron en un artículo que se publicó en línea en la edición de octubre de Molecular Therapy.
